Pfizer regrets 1.5 billion euro investment in France

Pfizer's French subsidiary believes it would not invest this major amount again due to a restrictive regulatory environment.

Published 30sem2 sources✓ ConfirmedNotableupdated 30sem

≈ 21sSpeed

The fact

This situation illustrates tensions between pharmaceutical companies and the French and European regulatory framework.

The Pfizer case raises questions about France's attractiveness for sensitive industrial investments.

2 sources — click a link to read an article on the topic:

Explore this topic

Auto-synthesis from 2 media sources · identified on April 15, 2026